Takeda Pharmaceutical downgraded by Morgan Stanley
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley downgraded Takeda Pharmaceutical from Overweight to Equal-Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/16/2023 | $20.00 | Neutral → Buy | BofA Securities |
| 7/19/2022 | $21.00 → $24.00 | Market Perform → Outperform | Cowen |
| 10/7/2021 | Overweight → Equal-Weight | Morgan Stanley |
Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight
BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00
Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously
3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry. Mos
Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave
2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o
-New Technology Optimizes Plasma Collection Resulting in Efficiency Gains -Helps Strengthen Plasma Supply Used to Produce Lifesaving and Life-Sustaining Medicines BioLife Plasma Services, part of Takeda (NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025. This press release features multimedia. View the full relea
Annual Grants Deepen Takeda's Commitment to Improving Health Through Community-Based Programs Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem See the full release at Takeda.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250430215346/en/ Media Contact: Takeda Media Relations [email protected]
Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) Core Operating Profit Increase of +10.1% at CER; Core OP Margin Climbs to 28.5% Reported Operating Profit +86.3% at AER Reflects Lower Impairment of Intangible Assets Compared to FY2023 Raises Adjusted Free Cash Flow Forecast Range by JPY 150.0 billion to JPY550.0 - JPY650.0 billion Announces Share Buyback of up to JPY 100.0 billion Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth &